Nature of Proceedings: (2) Demurrers; Pro Hac Vice Application
On November 19, 2013, plaintiff Derik Barseghian was involved in an accident and treated at defendant Santa Barbara Cottage Hospital (Hospital). (Complaint, ¶ 46.) That day, Barseghian underwent a CT scan of his brain, which did not evidence edema. (Complaint, ¶ 47.)
On November 20, 2013, Barseghian was discharged from Hospital with a discharge diagnosis of concussion syndrome. (Complaint, ¶ 48.) On discharge, defendant Juliette Fish, N.P., under the supervision of defendant James Timothy Dunn, M.D., and as modified by registered pharmacist defendant Ryan Griffith Sahlin, prescribed for Barseghian a pharmaceutical drug, dexamethasone. (Complaint, ¶¶ 37, 49.) Dexamethasone is a generic drug manufactured, designed, serviced, merchandised, advertised, promoted, marketed, or sold by defendants Roxane Laboratories, Inc., Boehringer Ingelheim Roxane, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Hikma Americas, Inc. (C
Hearing Date
March 04, 2016
For full print and download access, please subscribe at https://www.trellis.law/.
Nature of Proceedings: (2) Demurrers; Pro Hac Vice Application
On November 19, 2013, plaintiff Derik Barseghian was involved in an accident and treated at defendant Santa Barbara Cottage Hospital (Hospital). (Complaint, ¶ 46.) That day, Barseghian underwent a CT scan of his brain, which did not evidence edema. (Complaint, ¶ 47.)
On November 20, 2013, Barseghian was discharged from Hospital with a discharge diagnosis of concussion syndrome. (Complaint, ¶ 48.) On discharge, defendant Juliette Fish, N.P., under the supervision of defendant James Timothy Dunn, M.D., and as modified by registered pharmacist defendant Ryan Griffith Sahlin, prescribed for Barseghian a pharmaceutical drug, dexamethasone. (Complaint, ¶¶ 37, 49.) Dexamethasone is a generic drug manufactured, designed, serviced, merchandised, advertised, promoted, marketed, or sold by defendants Roxane Laboratories, Inc., Boehringer Ingelheim Roxane, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Hikma Americas, Inc. (C